AI assistant
Sending…
Tempest Therapeutics, Inc. — Director's Dealing 2018
Jan 22, 2018
34632_dirs_2018-01-22_415c74c0-954b-428b-b36e-d5a7c6db248a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2018-01-16
Reporting Person: Lillie James Woodruff (Chief Scientific Officer)
More from Tempest Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 22
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Capital/Financing Update
2026
Apr 10
Capital/Financing Update
2026
Apr 10
Regulatory Filings
2026
Mar 31